Madrigal Pharmaceuticals (MDGL) PT Raised to $174 at B.Riley/FBR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $396.32 -8.08%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
B.Riley/FBR analyst Mayank Mamtani raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $174.00 (from $134.00) while maintaining a Buy rating.
You May Also Be Interested In
- Madrigal Pharmaceuticals (MDGL) PT Raised to $760 at Citi
- Avita Medical Ltd. (RCEL) PT Raised to $20 at TD Cowen
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
